BIOMAT Database Logo BIOMAT Database Logo

A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. 1994

S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
University of Southern California School of Medicine, Department of Obstetrics and Gynecology, Los Angeles.

A core design contraceptive vaginal ring (CVR) releasing 650 mcg of norethindrone acetate (NA) and 10, 20, 30 or 65 mcg of ethinyl estradiol (EE) daily was developed and tested in 99 women. The CVR inhibited ovulation well with 30 or 65 mcg EE. Vaginal bleeding was better controlled than in 23 control women using NA/EE oral contraceptives. Side effects were comparable to controls for the 20 and 30 mcg EE CVR. The 65 mcg EE CVR resulted in an unacceptably high level of nausea. The 20 and 30 mcg EE CVR caused an increase in serum HDL cholesterol and triglycerides. Total cholesterol was unchanged. Angiotensinogen and sex hormone binding globulin-binding capacity were increased in a subgroup of the 20 and 30 mcg EE CVR subjects, similar to that of 20 controls using EE/gestodene oral contraceptives. This new CVR offers an excellent contraceptive alternative with the best performance provided by the 30 mcg EE dose.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008183 Luteal Phase The period in the MENSTRUAL CYCLE that follows OVULATION, characterized by the development of CORPUS LUTEUM, increase in PROGESTERONE production by the OVARY and secretion by the glandular epithelium of the ENDOMETRIUM. The luteal phase begins with ovulation and ends with the onset of MENSTRUATION. Menstrual Cycle, Luteal Phase,Menstrual Cycle, Secretory Phase,Menstrual Secretory Phase,Postovulatory Phase,Phase, Luteal,Phase, Postovulatory,Secretory Phase, Menstrual
D008597 Menstrual Cycle The period from onset of one menstrual bleeding (MENSTRUATION) to the next in an ovulating woman or female primate. The menstrual cycle is regulated by endocrine interactions of the HYPOTHALAMUS; the PITUITARY GLAND; the ovaries; and the genital tract. The menstrual cycle is divided by OVULATION into two phases. Based on the endocrine status of the OVARY, there is a FOLLICULAR PHASE and a LUTEAL PHASE. Based on the response in the ENDOMETRIUM, the menstrual cycle is divided into a proliferative and a secretory phase. Endometrial Cycle,Ovarian Cycle,Cycle, Endometrial,Cycle, Menstrual,Cycle, Ovarian,Cycles, Endometrial,Cycles, Menstrual,Cycles, Ovarian,Endometrial Cycles,Menstrual Cycles,Ovarian Cycles
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009640 Norethindrone A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD
D003274 Contraceptive Devices, Female Contraceptive devices used by females. Cervical Cap,Coiled Spring,Vaginal Diaphragm,Vaginal Rings,Vaginal Shield,Vaginal Sponge,Cap, Cervical,Caps, Cervical,Cervical Caps,Coiled Springs,Contraceptive Device, Female,Device, Female Contraceptive,Devices, Female Contraceptive,Diaphragm, Vaginal,Diaphragms, Vaginal,Female Contraceptive Device,Female Contraceptive Devices,Ring, Vaginal,Rings, Vaginal,Shield, Vaginal,Shields, Vaginal,Sponge, Vaginal,Sponges, Vaginal,Spring, Coiled,Springs, Coiled,Vaginal Diaphragms,Vaginal Ring,Vaginal Shields,Vaginal Sponges
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005260 Female Females

Related Publications

S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
May 1999, Contraception,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.
August 2007, Expert opinion on pharmacotherapy,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users.
July 2023, Journal of women's health (2002),
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Gabapentin does not interact with a contraceptive regimen of norethindrone acetate and ethinyl estradiol.
April 1998, Neurology,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
January 1984, Upsala journal of medical sciences,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception.
May 2020, American family physician,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate.
September 2020, Contraception,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
A new low dose norethindrone acetate (0.6 mg) ethinyl estradiol (30 mcg) combination oral contraceptive.
March 1974, The Journal of reproductive medicine,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.
June 2019, Contraception,
S A Ballagh, and D R Mishell, and M Lacarra, and D Shoupe, and T M Jackanicz, and P Eggena
Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol.
February 2001, Contraception,
Copied contents to your clipboard!